Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
22 "Minho Shong"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Review Articles
Thyroid
Metabolic Reprogramming in Thyroid Cancer
Sang-Hyeon Ju, Minchul Song, Joung Youl Lim, Yea Eun Kang, Hyon-Seung Yi, Minho Shong
Endocrinol Metab. 2024;39(3):425-444.   Published online June 10, 2024
DOI: https://doi.org/10.3803/EnM.2023.1802
  • 809 View
  • 71 Download
AbstractAbstract PDFPubReader   ePub   
Thyroid cancer is a common endocrine malignancy with increasing incidence globally. Although most cases can be treated effectively, some cases are more aggressive and have a higher risk of mortality. Inhibiting RET and BRAF kinases has emerged as a potential therapeutic strategy for the treatment of thyroid cancer, particularly in cases of advanced or aggressive disease. However, the development of resistance mechanisms may limit the efficacy of these kinase inhibitors. Therefore, developing precise strategies to target thyroid cancer cell metabolism and overcome resistance is a critical area of research for advancing thyroid cancer treatment. In the field of cancer therapeutics, researchers have explored combinatorial strategies involving dual metabolic inhibition and metabolic inhibitors in combination with targeted therapy, chemotherapy, and immunotherapy to overcome the challenge of metabolic plasticity. This review highlights the need for new therapeutic approaches for thyroid cancer and discusses promising metabolic inhibitors targeting thyroid cancer. It also discusses the challenges posed by metabolic plasticity in the development of effective strategies for targeting cancer cell metabolism and explores the potential advantages of combined metabolic targeting.
Close layer
Thyroid
Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
Sang-Hyeon Ju, Seong Eun Lee, Yea Eun Kang, Minho Shong
Endocrinol Metab. 2022;37(1):53-61.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.1402
  • 4,055 View
  • 191 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDFPubReader   ePub   
Cancer therapies targeting genetic alterations are a topic of great interest in the field of thyroid cancer, which frequently harbors mutations in the RAS, RAF, and RET genes. Unfortunately, U.S. Food and Drug Administration-approved BRAF inhibitors have relatively low therapeutic efficacy against BRAF-mutant thyroid cancer; in addition, the cancer often acquires drug resistance, which prevents effective treatment. Recent advances in genomics and transcriptomics are leading to a more complete picture of the range of mutations, both driver and messenger, present in thyroid cancer. Furthermore, our understanding of cancer suggests that oncogenic mutations drive tumorigenesis and induce rewiring of cancer cell metabolism, which promotes survival of mutated cells. Synthetic lethality (SL) is a method of neutralizing mutated genes that were previously considered untargetable by traditional genotype-targeted treatments. Because these metabolic events are specific to cancer cells, we have the opportunity to develop new therapies that target tumor cells specifically without affecting healthy tissue. Here, we describe developments in metabolism-based cancer therapy, focusing on the concept of metabolic SL in thyroid cancer. Finally, we discuss the essential implications of metabolic reprogramming and its role in the future direction of SL for thyroid cancer.

Citations

Citations to this article as recorded by  
  • Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer
    Aliya Lakhani, Da Hyun Kang, Yea Eun Kang, Junyoung O. Park
    Endocrinology and Metabolism.2023; 38(6): 619.     CrossRef
  • The Role of De novo Serine Biosynthesis from Glucose in Papillary Thyroid Cancer
    Seong Eun Lee, Na Rae Choi, Jin-Man Kim, Mi Ae Lim, Bon Seok Koo, Yea Eun Kang
    International Journal of Thyroidology.2023; 16(2): 175.     CrossRef
Close layer
Corrigendum
Miscellaneous
Corrigendum: Correction of Acknowledgments. Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinol Metab. 2022;37(1):181-182.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.104
Corrects: Endocrinol Metab 2021;36(2):359
  • 3,140 View
  • 113 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study
    Sungho Bea, Heejun Son, Jae Hyun Bae, Sun Wook Cho, Ju‐Young Shin, Young Min Cho
    Diabetes, Obesity and Metabolism.2024; 26(1): 108.     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
Expression of LONP1 Is High in Visceral Adipose Tissue in Obesity, and Is Associated with Glucose and Lipid Metabolism
Ju Hee Lee, Saet-Byel Jung, Seong Eun Lee, Ji Eun Kim, Jung Tae Kim, Yea Eun Kang, Seul Gi Kang, Hyon-Seung Yi, Young Bok Ko, Ki Hwan Lee, Bon Jeong Ku, Minho Shong, Hyun Jin Kim
Endocrinol Metab. 2021;36(3):661-671.   Published online June 22, 2021
DOI: https://doi.org/10.3803/EnM.2021.1023
  • 4,882 View
  • 155 Download
  • 8 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The nature and role of the mitochondrial stress response in adipose tissue in relation to obesity are not yet known. To determine whether the mitochondrial unfolded protein response (UPRmt) in adipose tissue is associated with obesity in humans and rodents.
Methods
Visceral adipose tissue (VAT) was obtained from 48 normoglycemic women who underwent surgery. Expression levels of mRNA and proteins were measured for mitochondrial chaperones, intrinsic proteases, and components of electron-transport chains. Furthermore, we systematically analyzed metabolic phenotypes with a large panel of isogenic BXD inbred mouse strains and Genotype-Tissue Expression (GTEx) data.
Results
In VAT, expression of mitochondrial chaperones and intrinsic proteases localized in inner and outer mitochondrial membranes was not associated with body mass index (BMI), except for the Lon protease homolog, mitochondrial, and the corresponding gene LONP1, which showed high-level expression in the VAT of overweight or obese individuals. Expression of LONP1 in VAT positively correlated with BMI. Analysis of the GTEx database revealed that elevation of LONP1 expression is associated with enhancement of genes involved in glucose and lipid metabolism in VAT. Mice with higher Lonp1 expression in adipose tissue had better systemic glucose metabolism than mice with lower Lonp1 expression.
Conclusion
Expression of mitochondrial LONP1, which is involved in the mitochondrial quality control stress response, was elevated in the VAT of obese individuals. In a bioinformatics analysis, high LONP1 expression in VAT was associated with enhanced glucose and lipid metabolism.

Citations

Citations to this article as recorded by  
  • LONP1 ameliorates liver injury and improves gluconeogenesis dysfunction in acute-on-chronic liver failure
    Muchen Wu, Jing Wu, Kai Liu, Minjie Jiang, Fang Xie, Xuehong Yin, Jushan Wu, Qinghua Meng
    Chinese Medical Journal.2024; 137(2): 190.     CrossRef
  • Tissue‐specific roles of mitochondrial unfolded protein response during obesity
    Fernanda S. Carneiro, Carlos K. Katashima, Joshua D. Dodge, Dennys E. Cintra, José Rodrigo Pauli, Adelino S. R. Da Silva, Eduardo R. Ropelle
    Obesity Reviews.2024;[Epub]     CrossRef
  • Mitochondrial quality control proteases and their modulation for cancer therapy
    Jiangnan Zhang, Wenliang Qiao, Youfu Luo
    Medicinal Research Reviews.2023; 43(2): 399.     CrossRef
  • Effects of Obesity and Calorie Restriction on Cancer Development
    Ekaterina Sergeeva, Tatiana Ruksha, Yulia Fefelova
    International Journal of Molecular Sciences.2023; 24(11): 9601.     CrossRef
  • Mitochondrial Dysfunction Associated with mtDNA in Metabolic Syndrome and Obesity
    Natalia Todosenko, Olga Khaziakhmatova, Vladimir Malashchenko, Kristina Yurova, Maria Bograya, Maria Beletskaya, Maria Vulf, Natalia Gazatova, Larisa Litvinova
    International Journal of Molecular Sciences.2023; 24(15): 12012.     CrossRef
  • Down‐regulation of Lon protease 1 lysine crotonylation aggravates mitochondrial dysfunction in polycystic ovary syndrome
    Yuan Xie, Shuwen Chen, Zaixin Guo, Ying Tian, Xinyu Hong, Penghui Feng, Qiu Xie, Qi Yu
    MedComm.2023;[Epub]     CrossRef
  • The mitochondrial unfolded protein response: A multitasking giant in the fight against human diseases
    Zixin Zhou, Yumei Fan, Ruikai Zong, Ke Tan
    Ageing Research Reviews.2022; 81: 101702.     CrossRef
Close layer
Clinical Study
Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinol Metab. 2021;36(2):359-364.   Published online March 23, 2021
DOI: https://doi.org/10.3803/EnM.2020.890
Correction in: Endocrinol Metab 2022;37(1):181
  • 6,148 View
  • 208 Download
  • 17 Web of Science
  • 17 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.
Methods
Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.
Conclusion
KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.

Citations

Citations to this article as recorded by  
  • Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines
    Min Joo Kim, Jae Hoon Moon, Eun Kyung Lee, Young Shin Song, Kyong Yeun Jung, Ji Ye Lee, Ji-hoon Kim, Kyungsik Kim, Sue K. Park, Young Joo Park
    Endocrinology and Metabolism.2024; 39(1): 47.     CrossRef
  • It Is Time to Understand the Additional Benefits of Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Kyeong Jin Kim
    Endocrinology and Metabolism.2024; 39(1): 95.     CrossRef
  • Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
    Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2024; 39(1): 152.     CrossRef
  • Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
    Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2024; 39(1): 152.     CrossRef
  • Thyroid‐Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low‐Risk Papillary Thyroid Microcarcinoma in Adults
    Yasuhiro Ito, Akira Miyauchi, Makoto Fujishima, Takuya Noda, Tsutomu Sano, Takahiro Sasaki, Taketoshi Kishi, Tomohiko Nakamura
    World Journal of Surgery.2023; 47(2): 392.     CrossRef
  • Thyroid FNA cytology: The Eastern versus Western perspectives
    Mitsuyoshi Hirokawa, Manon Auger, Chan Kwon Jung, Fabiano Mesquita Callegari
    Cancer Cytopathology.2023; 131(7): 415.     CrossRef
  • To Screen or Not to Screen?
    Do Joon Park
    Endocrinology and Metabolism.2023; 38(1): 69.     CrossRef
  • Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
    Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park
    Endocrinology and Metabolism.2023; 38(1): 93.     CrossRef
  • Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience
    Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Akihiro Miya, Naoyoshi Onoda, Minoru Kihara, Takuya Higashiyama, Hiroo Masuoka, Shiori Kawano, Takahiro Sasaki, Mitsushige Nishikawa, Shuji Fukata, Takashi Akamizu, Mitsuru Ito, Eijun Nishihara, Mako Hisakad
    Thyroid®.2023; 33(7): 817.     CrossRef
  • Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status
    Masashi Yamamoto, Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Takahiro Sasaki, Takumi Kudo
    Thyroid®.2023; 33(10): 1182.     CrossRef
  • Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population
    Han-Sang Baek, Jeonghoon Ha, Kwangsoon Kim, Jaseong Bae, Jeong Soo Kim, Sungju Kim, Dong-Jun Lim, Chulmin Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Optimal Cutoff Values of the Contact Angle of Tumor on Sonography System for Predicting Extrathyroidal Extension of Papillary Thyroid Carcinoma by Tumor Location
    Ik Beom Shin, Do Hoon Koo, Dong Sik Bae
    Clinical Medicine Insights: Oncology.2023;[Epub]     CrossRef
  • Thermal Ablation for Papillary Thyroid Microcarcinoma Located in The Isthmus: a Study With 3 Years Of Follow-Up
    Lin Zheng, Fang-yi Liu, Jie Yu, Zhi-gang Cheng, Xiao-ling Yu, Xiao-cong Dong, Zhi-yu Han, Ping Liang
    Future Oncology.2022; 18(4): 471.     CrossRef
  • Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000–2018)
    Elisa Pasqual, Julie Ann Sosa, Yingxi Chen, Sara J. Schonfeld, Amy Berrington de González, Cari M. Kitahara
    Thyroid.2022; 32(4): 397.     CrossRef
  • Management of Low-Risk Thyroid Cancers: Is Active Surveillance a Valid Option? A Systematic Review of the Literature
    Renato Patrone, Nunzio Velotti, Stefania Masone, Alessandra Conzo, Luigi Flagiello, Chiara Cacciatore, Marco Filardo, Vincenza Granata, Francesco Izzo, Domenico Testa, Stefano Avenia, Alessandro Sanguinetti, Andrea Polistena, Giovanni Conzo
    Journal of Clinical Medicine.2021; 10(16): 3569.     CrossRef
  • Cost-Effectiveness Analysis of Active Surveillance Compared to Early Surgery in Small Papillary Thyroid Cancer: A Systemic Review
    Han-sang Baek, Chai-ho Jeong, Jeonghoon Ha, Ja-Seong Bae, Jeong-soo Kim, Dong-Jun Lim, Chul-Min Kim
    Cancer Management and Research.2021; Volume 13: 6721.     CrossRef
  • Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(4): 717.     CrossRef
Close layer
Namgok Lecture 2020
Obesity and Metabolism
Cellular and Intercellular Homeostasis in Adipose Tissue with Mitochondria-Specific Stress
Min Jeong Choi, Saet-Byel Jung, Joon Young Chang, Minho Shong
Endocrinol Metab. 2021;36(1):1-11.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.956
  • 6,021 View
  • 230 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Paracrine interactions are imperative for the maintenance of adipose tissue intercellular homeostasis, and intracellular organelle dysfunction results in local and systemic alterations in metabolic homeostasis. It is currently accepted that mitochondrial proteotoxic stress activates the mitochondrial unfolded protein response (UPRmt) in vitro and in vivo. The induction of mitochondrial chaperones and proteases during the UPRmt is a key cell-autonomous mechanism of mitochondrial quality control. The UPRmt also affects systemic metabolism through the secretion of cell non-autonomous peptides and cytokines (hereafter, metabokines). Mitochondrial function in adipose tissue plays a pivotal role in whole-body metabolism and human diseases. Despite continuing interest in the role of the UPRmt and quality control pathways of mitochondria in energy metabolism, studies on the roles of the UPRmt and metabokines in white adipose tissue are relatively sparse. Here, we describe the role of the UPRmt in adipose tissue, including adipocytes and resident macrophages, and the interactive roles of cell non-autonomous metabokines, particularly growth differentiation factor 15, in local adipose cellular homeostasis and systemic energy metabolism.

Citations

Citations to this article as recorded by  
  • Imeglimin modulates mitochondria biology and facilitates mitokine secretion in 3T3-L1 adipocytes
    Nobuhiko Takahashi, Atsushi P. Kimura, Takayuki Yoshizaki, Kazumasa Ohmura
    Life Sciences.2024; 349: 122735.     CrossRef
  • Mitochondrial stress-induced GFRAL signaling controls diurnal food intake and anxiety-like behavior
    Carla Igual Gil, Bethany M Coull, Wenke Jonas, Rachel N Lippert, Susanne Klaus, Mario Ost
    Life Science Alliance.2022; 5(11): e202201495.     CrossRef
  • Stress-induced FGF21 and GDF15 in obesity and obesity resistance
    Susanne Keipert, Mario Ost
    Trends in Endocrinology & Metabolism.2021; 32(11): 904.     CrossRef
Close layer
Original Articles
Clinical Study
Genetic Analysis of CLCN7 in an Old Female Patient with Type II Autosomal Dominant Osteopetrosis
Seon Young Kim, Younghak Lee, Yea Eun Kang, Ji Min Kim, Kyong Hye Joung, Ju Hee Lee, Koon Soon Kim, Hyun Jin Kim, Bon Jeong Ku, Minho Shong, Hyon-Seung Yi
Endocrinol Metab. 2018;33(3):380-386.   Published online September 18, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.380
  • 4,399 View
  • 60 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Type II autosomal dominant osteopetrosis (ADO II) is a rare genetically heterogeneous disorder characterized by osteosclerosis and increased bone mass, predominantly involving spine, pelvis, and skull. It is closely related to functional defect of osteoclasts caused by chloride voltage-gated channel 7 (CLCN7) gene mutations. In this study, we aimed to identify the pathogenic mutation in a Korean patient with ADO II using whole exome sequencing.

Methods

We evaluated the clinical, biochemical, and radiographic analysis of a 68-year-old woman with ADO II. We also performed whole exome sequencing to identify pathogenic mutation of a rare genetic disorder of the skeleton. Moreover, a polymorphism phenotyping program, Polymorphism Phenotyping v2 (PolyPhen-2), was used to assess the effect of the identified mutation on protein function.

Results

Whole exome sequencing using peripheral leukocytes revealed a heterozygous c.296A>G missense mutation in the CLCN7 gene. The mutation was also confirmed using Sanger sequencing. The mutation c.296A>G was regarded to have a pathogenic effect by PolyPhen-2 software.

Conclusion

We detect a heterozygous mutation in CLCN7 gene of a patient with ADO II, which is the first report in Korea. Our present findings suggest that symptoms and signs of ADO II patient having a c.296A>G mutation in CLCN7 may appear at a very late age. The present study would also enrich the database of CLCN7 mutations and improve our understanding of ADO II.

Citations

Citations to this article as recorded by  
  • Autosomal dominant osteopetrosis type II resulting from a de novo mutation in the CLCN7 gene: A case report
    Xiu-Li Song, Li-Yuan Peng, Dao-Wen Wang, Hong Wang
    World Journal of Clinical Cases.2022; 10(20): 6936.     CrossRef
  • Magnetic resonance findings in a Cavalier King Charles spaniel with osteopetrosis, Chiari‐like malformation and syringomyelia
    Ricardo Fernandes, C J Jordan, Colin Driver
    Veterinary Record Case Reports.2019;[Epub]     CrossRef
Close layer
Clinical Study
The Eosinophil Count Tends to Be Negatively Associated with Levels of Serum Glucose in Patients with Adrenal Cushing Syndrome
Younghak Lee, Hyon-Seung Yi, Hae Ri Kim, Kyong Hye Joung, Yea Eun Kang, Ju Hee Lee, Koon Soon Kim, Hyun Jin Kim, Bon Jeong Ku, Minho Shong
Endocrinol Metab. 2017;32(3):353-359.   Published online September 18, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.3.353
  • 8,376 View
  • 46 Download
  • 6 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   
Background

Cushing syndrome is characterized by glucose intolerance, cardiovascular disease, and an enhanced systemic inflammatory response caused by chronic exposure to excess cortisol. Eosinopenia is frequently observed in patients with adrenal Cushing syndrome, but the relationship between the eosinophil count in peripheral blood and indicators of glucose level in patients with adrenal Cushing syndrome has not been determined.

Methods

A retrospective study was undertaken of the clinical and laboratory findings of 40 patients diagnosed with adrenal Cushing syndrome at Chungnam National University Hospital from January 2006 to December 2016. Clinical characteristics, complete blood cell counts with white blood cell differential, measures of their endocrine function, description of imaging studies, and pathologic findings were obtained from their medical records.

Results

Eosinophil composition and count were restored by surgical treatment of all of the patients with adrenal Cushing disease. The eosinophil count was inversely correlated with serum and urine cortisol, glycated hemoglobin, and inflammatory markers in the patients with adrenal Cushing syndrome.

Conclusion

Smaller eosinophil populations in patients with adrenal Cushing syndrome tend to be correlated with higher levels of blood sugar and glycated hemoglobin. This study suggests that peripheral blood eosinophil composition or count may be associated with serum glucose levels in patients with adrenal Cushing syndrome.

Citations

Citations to this article as recorded by  
  • Association between Eosinophil Count and Cortisol Concentrations in Equids Admitted in the Emergency Unit with Abdominal Pain
    María Villalba-Orero, María Dolores Contreras-Aguilar, Jose Joaquín Cerón, Beatriz Fuentes-Romero, Marta Valero-González, María Martín-Cuervo
    Animals.2024; 14(1): 164.     CrossRef
  • Inverse relationship between eosinophil profiles and serum glucose concentration in dogs with naturally occurring hypercortisolism
    Jimin Oh, Dohee Lee, Taesik Yun, Yoonhoi Koo, Yeon Chae, Mhan-Pyo Yang, Byeong-Teck Kang, Hakhyun Kim
    Domestic Animal Endocrinology.2022; 80: 106727.     CrossRef
  • Serum Cortisol and Its Correlation with Leucocyte Profile and Circulating Lipids in Donkeys (Equus asinus)
    Daniela Alberghina, Alessandra Statelli, Vincenzo Monteverde, Irene Vazzana, Giuseppe Cascone, Michele Panzera
    Animals.2022; 12(7): 841.     CrossRef
  • Changes in leukocytes and CRP in different stages of major depression
    Deepti Singh, Paul C. Guest, Henrik Dobrowolny, Veronika Vasilevska, Gabriela Meyer-Lotz, Hans-Gert Bernstein, Katrin Borucki, Alexandra Neyazi, Bernhard Bogerts, Roland Jacobs, Johann Steiner
    Journal of Neuroinflammation.2022;[Epub]     CrossRef
  • HIF1α is a direct regulator of steroidogenesis in the adrenal gland
    Deepika Watts, Johanna Stein, Ana Meneses, Nicole Bechmann, Ales Neuwirth, Denise Kaden, Anja Krüger, Anupam Sinha, Vasileia Ismini Alexaki, Luis Gustavo Perez-Rivas, Stefan Kircher, Antoine Martinez, Marily Theodoropoulou, Graeme Eisenhofer, Mirko Peitz
    Cellular and Molecular Life Sciences.2021; 78(7): 3577.     CrossRef
  • The Immune System in Cushing’s Syndrome
    Valeria Hasenmajer, Emilia Sbardella, Francesca Sciarra, Marianna Minnetti, Andrea M. Isidori, Mary Anna Venneri
    Trends in Endocrinology & Metabolism.2020; 31(9): 655.     CrossRef
Close layer
Review Article
Thyroid
Mitochondrial Energy Metabolism and Thyroid Cancers
Junguee Lee, Joon Young Chang, Yea Eun Kang, Shinae Yi, Min Hee Lee, Kyong Hye Joung, Kun Soon Kim, Minho Shong
Endocrinol Metab. 2015;30(2):117-123.   Published online June 30, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.2.117
  • 4,586 View
  • 54 Download
  • 16 Web of Science
  • 16 Crossref
AbstractAbstract PDFPubReader   

Primary thyroid cancers including papillary, follicular, poorly differentiated, and anaplastic carcinomas show substantial differences in biological and clinical behaviors. Even in the same pathological type, there is wide variability in the clinical course of disease progression. The molecular carcinogenesis of thyroid cancer has advanced tremendously in the last decade. However, specific inhibition of oncogenic pathways did not provide a significant survival benefit in advanced progressive thyroid cancer that is resistant to radioactive iodine therapy. Accumulating evidence clearly shows that cellular energy metabolism, which is controlled by oncogenes and other tumor-related factors, is a critical factor determining the clinical phenotypes of cancer. However, the role and nature of energy metabolism in thyroid cancer remain unclear. In this article, we discuss the role of cellular energy metabolism, particularly mitochondrial energy metabolism, in thyroid cancer. Determining the molecular nature of metabolic remodeling in thyroid cancer may provide new biomarkers and therapeutic targets that may be useful in the management of refractory thyroid cancers.

Citations

Citations to this article as recorded by  
  • Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review
    Angelika Buczyńska, Maria Kościuszko, Adam Jacek Krętowski, Anna Popławska-Kita
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Liquid Biopsy as a Method for Minimally Invasive Diagnosis of Thyroid Cancer
    Tagir I. Rakhmatullin, Mark Jain, Larisa M. Samokhodskaya, Vladimir A. Zhivotov
    Journal of Clinical Practice.2023; 14(3): 69.     CrossRef
  • Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
    Sang-Hyeon Ju, Seong Eun Lee, Yea Eun Kang, Minho Shong
    Endocrinology and Metabolism.2022; 37(1): 53.     CrossRef
  • Monensin Inhibits Anaplastic Thyroid Cancer via Disrupting Mitochondrial Respiration and AMPK/mTOR Signaling
    Yanli Li, Qianshu Sun, Sisi Chen, Xiongjie Yu, Hongxia Jing
    Anti-Cancer Agents in Medicinal Chemistry.2022; 22(14): 2539.     CrossRef
  • Growth Differentiation Factor 15 is a Cancer Cell-Induced Mitokine That Primes Thyroid Cancer Cells for Invasiveness
    Yea Eun Kang, Jin Man Kim, Mi Ae Lim, Seong Eun Lee, Shinae Yi, Jung Tae Kim, Chan Oh, Lihua Liu, Yanli Jin, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Jeong Ho Lee, Hyun Jung Kim, Hyun Yong Koh, Sangmi Jun, Sun Wook Cho, Minho Shong, Bon Seok Koo
    Thyroid.2021; 31(5): 772.     CrossRef
  • Clinical Significance of the D-Loop Gene Mutation in Mitochondrial DNA in Laryngeal Cancer
    Lei Wang, He-Xiang Cheng, Yan-Hui Zhou, Min Ma
    OncoTargets and Therapy.2021; Volume 14: 3461.     CrossRef
  • Transcriptomic and Genetic Associations between Alzheimer’s Disease, Parkinson’s Disease, and Cancer
    Jaume Forés-Martos, Cesar Boullosa, David Rodrigo-Domínguez, Jon Sánchez-Valle, Beatriz Suay-García, Joan Climent, Antonio Falcó, Alfonso Valencia, Joan Anton Puig-Butillé, Susana Puig, Rafael Tabarés-Seisdedos
    Cancers.2021; 13(12): 2990.     CrossRef
  • KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma
    Zheng Wang, Xinguang Qiu, Hao Zhang, Weihan Li
    Journal of Biochemical and Molecular Toxicology.2020;[Epub]     CrossRef
  • Metabolic reprogramming related to whole-chromosome instability in models for Hürthle cell carcinoma
    Ruben D. Addie, Sarantos Kostidis, Willem E. Corver, Jan Oosting, Sepideh Aminzadeh-Gohari, René G. Feichtinger, Barbara Kofler, Mehtap Derya Aydemirli, Martin Giera, Hans Morreau
    Scientific Reports.2020;[Epub]     CrossRef
  • Inhibition of mitochondrial respiration by tigecycline selectively targets thyroid carcinoma and increases chemosensitivity
    Yuehua Wang, Fei Xie, Dejie Chen, Ling Wang
    Clinical and Experimental Pharmacology and Physiology.2019; 46(10): 890.     CrossRef
  • Investigating Therapeutic Effects of Retinoic Acid on Thyroid Cancer via Protein-Protein Interaction Network Analysis
    Majid Rezaei-Tavirani, Mostafa Rezaei-Tavirani, Mona Zamanian Azodi
    International Journal of Cancer Management.2019;[Epub]     CrossRef
  • CASE REPORT: An Extensively Necrotic Hürthle-Cell Carcinoma Mimicked a Thyroid Abscess
    Sanders H. Lin, Shih-Ming Huang, Su-Lin Peng
    Clinical Thyroidology.2018; 30(11): 529.     CrossRef
  • Atovaquone enhances doxorubicin’s efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer
    Zhuo Lv, Xintong Yan, Liying Lu, Chun Su, Yin He
    Journal of Bioenergetics and Biomembranes.2018; 50(4): 263.     CrossRef
  • Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma
    Xianyin Lai, Christopher B. Umbricht, Kurt Fisher, Justin Bishop, Qiuying Shi, Shaoxiong Chen
    Journal of Proteomics.2017; 166: 59.     CrossRef
  • Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer
    Marika H Tesselaar, Johannes W Smit, James Nagarajah, Romana T Netea-Maier, Theo S Plantinga
    Journal of Molecular Endocrinology.2017; 59(4): R141.     CrossRef
  • Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis
    Nurul-Syakima Ab Mutalib, Sri Noraima Othman, Azliana Mohamad Yusof, Shahrun Niza Abdullah Suhaimi, Rohaizak Muhammad, Rahman Jamal
    PeerJ.2016; 4: e2119.     CrossRef
Close layer
Original Article
Bone Metabolism
Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis
In-Jin Cho, Ho-Yeon Chung, Sung-Woon Kim, Jae-Won Lee, Tae-Won Lee, Hye-Soon Kim, Sin-Gon Kim, Han Seok Choi, Sung-Hee Choi, Chan Soo Shin, Ki-Won Oh, Yong-Ki Min, Jung-Min Koh, Yumie Rhee, Dong-Won Byun, Yoon-Sok Chung, Jeong Hyun Park, Dong Jin Chung, Minho Shong, Eun-Gyoung Hong, Chang Beom Lee, Ki Hyun Baek, Moo-Il Kang
Endocrinol Metab. 2015;30(3):272-279.   Published online December 9, 2014
DOI: https://doi.org/10.3803/EnM.2015.30.3.272
  • 4,770 View
  • 49 Download
  • 4 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   
Background

The present study evaluated the efficacy of a combination of ibandronate and cholecalciferol on the restoration of the levels of 25-hydroxyvitamin D (25[OH]D) and various bone markers in postmenopausal women with osteoporosis.

Methods

This was a randomized, double-blind, active-controlled, prospective 16-week clinical trial conducted in 20 different hospitals. A total of 201 postmenopausal women with osteoporosis were assigned randomly to one of two groups: the IBN group, which received a once-monthly pill containing 150 mg ibandronate (n=99), or the IBN+ group, which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol (n=102). Serum levels of 25(OH)D, parathyroid hormone (PTH), and various bone markers were assessed at baseline and at the end of a 16-week treatment period.

Results

After 16 weeks of treatment, the mean serum levels of 25(OH)D significantly increased from 21.0 to 25.3 ng/mL in the IBN+ group but significantly decreased from 20.6 to 17.4 ng/mL in the IBN group. Additionally, both groups exhibited significant increases in mean serum levels of PTH but significant decreases in serum levels of bone-specific alkaline phosphatase and C-telopeptide of type 1 collagen (CTX) at 16 weeks; no significant differences were observed between the groups. However, in subjects with a vitamin D deficiency, IBN+ treatment resulted in a significant decrease in serum CTX levels compared with IBN treatment.

Conclusion

The present findings demonstrate that a once-monthly pill containing ibandronate and cholecalciferol may be useful for the amelioration of vitamin D deficiency in patients with postmenopausal osteoporosis. Moreover, this treatment combination effectively decreased serum levels of resorption markers, especially in subjects with a vitamin D deficiency, over the 16-week treatment period.

Citations

Citations to this article as recorded by  
  • Effect of vitamin D supplementation or fortification on bone turnover markers in women: a systematic review and meta-analysis
    Nasrin Nasimi, Sanaz Jamshidi, Aida Askari, Nazanin Zolfaghari, Erfan Sadeghi, Mehran Nouri, Nick Bellissimo, Shiva Faghih
    British Journal of Nutrition.2024; 131(9): 1473.     CrossRef
  • Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women
    Dong-Yun Lee, Yoon-Sok Chung
    Scientific Reports.2022;[Epub]     CrossRef
  • Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis
    So Young Park, Moo-Il Kang, Hyung Moo Park, Yumie Rhee, Seong Hwan Moon, Hyun Koo Yoon, Jung-Min Koh, Jae Suk Chang, In Joo Kim, Ye Yeon Won, Ye Soo Park, Hoon Choi, Chan Soo Shin, Taek Rim Yoon, Sung-Cheol Yun, Ho-Yeon Chung
    Archives of Osteoporosis.2020;[Epub]     CrossRef
  • Efficacy and safety of vitamin D3 B.O.N intramuscular injection in Korean adults with vitamin D deficiency
    Han Seok Choi, Yoon-Sok Chung, Yong Jun Choi, Da Hea Seo, Sung-Kil Lim
    Osteoporosis and Sarcopenia.2016; 2(4): 228.     CrossRef
  • Pharmacologic treatment of osteoporosis
    Yong-Ki Min
    Journal of the Korean Medical Association.2016; 59(11): 847.     CrossRef
Close layer
Editorials
Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or Hurthle Cell Neoplasm and Risk of Malignancy.
Jung Uee Lee, Minho Shong
Endocrinol Metab. 2010;25(4):298-300.   Published online December 1, 2010
DOI: https://doi.org/10.3803/EnM.2010.25.4.298
  • 1,775 View
  • 23 Download
AbstractAbstract PDF
No abstract available.
Close layer
Identification of Growth Regulatory Factors in Medullary Thyroid Carcinoma Cell Line.
Young Suk Jo, Minho Shong
J Korean Endocr Soc. 2009;24(2):84-86.   Published online June 1, 2009
DOI: https://doi.org/10.3803/jkes.2009.24.2.84
  • 1,532 View
  • 16 Download
AbstractAbstract PDF
No abstract available.
Close layer
Original Article
Expression of miRNA 146a/b, 221 and 222 in Thyroid Cancer.
Young Suk Jo, Ihn Suk Lee, Woojeong Hong, In Sang Song, Minho Shong, Je Ryoung Kim
J Korean Endocr Soc. 2009;24(1):17-24.   Published online March 1, 2009
DOI: https://doi.org/10.3803/jkes.2009.24.1.17
  • 1,736 View
  • 22 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
miRNAs can be diagnostic markers and therapeutic targets in cancers, but few studies have been conducted in thyroid cancer. We investigated the expression levels of miRNA 146a/b, 221, and 222 which are important miRNAs in papillary thyroid cancers (PTCa), and verified their impact on clinicopathological factors. METHODS: We measured the expression of pre-miRNAs 146a/b, 221, and 222 in NPA cells treated with 10% fetal bovine serum (FBS) or in HEK293T cells transfected with RET/PTC3 or BRAFV600E expression vectors. We also investigated the relationship between miRNA expression levels in thyroid cancer tissue specimens and clinicopathological parameters. RESULTS: Growth stimulation with 10% FBS induced miRNA expressions in NPA cells, and transfection of RET/PTC3 and BRAFV600E also increased the expression of these miRNAs in HEK293T cells. Most (25 cases; 50%) of PTCa showed increased expression of miRNA-146a/b and 30 cases (60%) had elevated expression of miRNA-221 and miRNA-222 compared to normal thyroid samples from the contralateral lobe. However, increased miRNA expression did not correlate with clinicopathological factors. CONCLUSION: Expression of miRNA 146a/b, 221, and 222 was increased by BRAFV600E and RET/PTC3 rearrangement and might have a role in tumorigenesis in PTCa. However, expression levels of these miRNAs did not correlate with clinicopathological parameters of patients with PTCa.

Citations

Citations to this article as recorded by  
  • Expression of miRNA 146a/b, 221 and 222 in Thyroid Cancer
    Do Joon Park
    Journal of Korean Endocrine Society.2009; 24(1): 15.     CrossRef
Close layer
Case Report
A Case of Multiple Endocrine Neoplasia Type I with Atypical Clinical Course.
Yun Sun Choi, Youn Sun Bai, Bon Jeong Ku, Young Suk Jo, Young Kun Kim, Heung Kyu Ro, Minho Shong
J Korean Endocr Soc. 2008;23(4):266-271.   Published online August 1, 2008
DOI: https://doi.org/10.3803/jkes.2008.23.4.266
  • 1,990 View
  • 22 Download
  • 6 Crossref
AbstractAbstract PDF
Multiple endocrine neoplasia type 1 (MEN 1) is characterized by the combined occurrence of primary hyperparathyroidism, enteropancreatic tumors and anterior pituitary adenoma. Yet carcinoid tumors, adrenal adenoma and lipoma might exist simultaneously. Thymic carcinoid tumors, which are recognized as one of the causes of death for patients with MEN 1, are uncommon and their natural history has barely been investigated.

Citations

Citations to this article as recorded by  
  • A rare case of multiple endocrine neoplasia type 1 initially presenting as an asymptomatic, huge mediastinal mass: case report
    Ji Eun Jun, You-Cheol Hwang, Kyu Jeong Ahn, Ho Yeon Chung, In-Kyung Jeong
    BMC Endocrine Disorders.2021;[Epub]     CrossRef
  • A Case of Asymptomatic Multiple Endocrine Neoplasia Type I with Thymic Carcinoid
    Suk Ki Park, Moon Won Lee, In Sub Han, Young Joo Park, Sung Yong Han, Joon Woo Park, Bong Eun Lee, Gwang Ha Kim, Sang Soo Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2019; 19(1): 65.     CrossRef
  • Incidental metastatic mediastinal atypical carcinoid in a patient with parathyroid adenoma: a case report
    Zareen Kiran, Asma Ahmed, Owais Rashid, Saira Fatima, Faizan Malik, Saulat Fatimi, Mubassher Ikram
    Journal of Medical Case Reports.2017;[Epub]     CrossRef
  • Multiple Endocrine Neoplasia Type 1 Presenting with an Invasive Giant Prolactinoma
    Jinhoon Cha, Jin Seo Kim, Jung Suk Han, Yeon Won Park, Min Joo Kim, Yun Hyi Ku, Hong Il Kim
    The Korean Journal of Medicine.2016; 91(3): 300.     CrossRef
  • Genetic and Epigenetic Analysis in Korean Patients with Multiple Endocrine Neoplasia Type 1
    Yoon Jung Chung, Sena Hwang, Jong Ju Jeong, Sun Yong Song, Se Hoon Kim, Yumie Rhee
    Endocrinology and Metabolism.2014; 29(3): 270.     CrossRef
  • A Case of Asymptomatic Multiple Endocrine Neoplasia Type 1 Detected Incidentally on Health Screening
    Pyung-San Cho, Hoon Park, Guk-Haeng Lee, Myung-Chul Lee
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2012; 55(6): 373.     CrossRef
Close layer
Original Article
Change in Thyroid Autoantibodies According to the Clinical Course of Painless Thyroiditis Excluding Postpartum Thyroiditis.
Ihn Suk Lee, Young Suk Jo, Bon Jeong Ku, Minho Shong, Young Kun Kim, Heung kyu Ro
J Korean Endocr Soc. 2008;23(4):245-252.   Published online August 1, 2008
DOI: https://doi.org/10.3803/jkes.2008.23.4.245
  • 2,085 View
  • 19 Download
AbstractAbstract PDF
BACKGROUND
Painless thyroiditis is characterized by painless, destructive inflammation of the thyroid gland. Although thyroid autoantibodies are frequently detected in patients suffering from this condition, the clinical significance of these antibodies is not well understood. Therefore, this study was conducted to investigate the relationship between thyroid function and thyroid autoantibodies in painless thyroiditis according to clinical course. METHODS: Patients proven to have painless thyroiditis were retrospectively included in this study. We analyzed their clinical features, thyroid function and titers of thyroid autoantibodies according to clinical course, which was divided into three phases; thyrotoxic, hypothyroid and recovery. RESULTS: Of the 21 patients included in this study, 2 were male and 19 were female. During the thyrotoxic phase, the mean free T4 concentration was 4.03 (2~6.8) ng/mL and the mean concentration of thyroid stimulating hormone (TSH) was 0.02 (0.01~0.07) U/mL. In addition, the titer of antithyroglobulin antibody and antithyroid peroxidase antibody was 298 (4.8~995) U/mL and 3318 (0.1~25280) U/mL, respectively during this phase. During the hypothyroid phase, the mean TSH was 16.3 (4.3-49.5) U/mL and was found to be positively correlated with the level of free T4 observed during the thyrotoxic phase (r = 0.523, P = 0.031). During the recovery phase, the titer of antithyroglobulin antibody was significantly reduced to 180 (38~487) U/mL when compared with the titer taken during the thyrotoxic phase (P = 0.016). Additionally, during the hypothyroid phase, patients found to have antithyroid peroxidase antibody had a higher titer of TSH than those that did not (23.9 (6.5~49.5) vs. 11.2 (5.3~18.2) U/mL, P = 0.004). CONCLUSION: The titer of free T4 and the presence of antithyroid peroxidase observed during the thyrotoxic phase were related to the titer of TSH during hypothyroid phase. Additionally, the titer of antithyroglobulin antibody was significantly reduced during the recovery phase.
Close layer

Endocrinol Metab : Endocrinology and Metabolism